Skip to main content

A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma

Open
  • Protocol code: INCB001158-206
  • EudraCT code: 2018-004076-35
  • Service: Hematology and Hematotherapy
  • Principal investigator:  Gironella Mesa, Mercedes
  • Pathology: Tumors
  • Phase: Fase I